Aligos Therapeutics (ALGS) Cash from Operations (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Cash from Operations came in at 23128000.0 in Q1 2026, down 10.61% YoY from 25873908.61 in Q1 2025, and down 6.36% on a QoQ basis from 21745000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Cash from Operations (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Cash from Operations data on file, last reported at 23128000.0 in Q1 2026.
- Quarterly Cash from Operations fell 10.61% year-over-year to 23128000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 84722000.0 (down 7.37% YoY) and the FY2025 annual result came in at 82503000.0, down 2.18% from the prior year.
- Cash from Operations declined to 23128000.0 in Q1 2026, from 21745000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 13616000.0 in Q2 2023 to a low of 25035000.0 in Q2 2022.
- A 5-year average of 20280000.0 and a median of 20434000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 55.22% — and 2024, when it tumbled 43.16%.
- Tracing ALGS's Cash from Operations over 5 years: stood at 16783000.0 in 2022, then slumped by 35.01% to 22658000.0 in 2023, then increased by 18.78% to 18403000.0 in 2024, then dropped by 18.16% to 21745000.0 in 2025, then decreased by 6.36% to 23128000.0 in 2026.
- The last three Cash from Operations figures came in at 23128000.0 (Q1 2026), 21745000.0 (Q4 2025), and 24345000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - | -24.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.95 Mn |
| Jun 30, 2026 | -24.95 Mn |
| Mar 31, 2026 | -23.13 Mn |
| Mar 31, 2026 | -23.13 Mn |
| Dec 31, 2025 | -21.75 Mn |
| Dec 31, 2025 | -21.75 Mn |
| Sep 30, 2025 | -24.35 Mn |
| Sep 30, 2025 | -24.35 Mn |
| Jun 30, 2025 | -15.50 Mn |
| Jun 30, 2025 | -15.50 Mn |
| Mar 31, 2025 | -20.91 Mn |
| Mar 31, 2025 | -20.91 Mn |
| Dec 31, 2024 | -18.40 Mn |
| Dec 31, 2024 | -18.40 Mn |
| Sep 30, 2024 | -20.10 Mn |
| Sep 30, 2024 | -20.10 Mn |
| Jun 30, 2024 | -19.49 Mn |
| Jun 30, 2024 | -19.49 Mn |
| Mar 31, 2024 | -22.75 Mn |
| Mar 31, 2024 | -22.75 Mn |